News
EIGRQ
8.50
NaN%
--
Weekly Report: what happened at EIGRQ last week (0923-0927)?
Weekly Report · 09/30 10:50
Weekly Report: what happened at EIGRQ last week (0916-0920)?
Weekly Report · 09/23 10:50
Weekly Report: what happened at EIGRQ last week (0909-0913)?
Weekly Report · 09/16 10:42
Amylyx Pharmaceuticals: Management Ambitiously Navigates Challenges
Seeking Alpha · 09/09 12:39
Weekly Report: what happened at EIGRQ last week (0902-0906)?
Weekly Report · 09/09 10:50
Eiger BioPharmaceuticals Files for Chapter 11, Warns Investors
TipRanks · 09/03 10:47
Weekly Report: what happened at EIGRQ last week (0826-0830)?
Weekly Report · 09/02 10:53
Weekly Report: what happened at EIGRQ last week (0819-0823)?
Weekly Report · 08/26 10:51
Weekly Report: what happened at EIGRQ last week (0812-0816)?
Weekly Report · 08/19 10:41
Weekly Report: what happened at EIGRQ last week (0805-0809)?
Weekly Report · 08/12 10:43
Weekly Report: what happened at EIGRQ last week (0729-0802)?
Weekly Report · 08/05 10:51
Eiger BioPharmaceuticals Issues Chapter 11 Financial Update
TipRanks · 08/01 10:49
Weekly Report: what happened at EIGRQ last week (0722-0726)?
Weekly Report · 07/29 10:43
Weekly Report: what happened at EIGRQ last week (0715-0719)?
Weekly Report · 07/22 10:44
Eiger BioPharmaceuticals Announces Bankruptcy and Liquidation Plan
TipRanks · 07/16 10:51
Weekly Report: what happened at EIGRQ last week (0708-0712)?
Weekly Report · 07/15 10:41
Why Is Small Cap Amylyx Pharmaceuticals Stock Trading Higher On Wednesday?
Benzinga · 07/10 19:32
Amylyx jumps on acquisition of Eiger’s GLP-1 drug
Seeking Alpha · 07/10 19:14
Amylyx Pharmaceuticals Acquired Avexitide From Eiger Biopharmaceuticals, For The Potential Treatment Of Hyper Insulinemic Hypoglycemia For $35.1M
Benzinga · 07/10 11:04
*Amylyx Pharmaceuticals: FDA Has Agreed to the Primary Endpoint Expected to Be Utilized in Phase 3 >AMLX
Dow Jones · 07/10 11:03
More
Webull provides a variety of real-time EIGRQ stock news. You can receive the latest news about Eiger Biopharma through multiple platforms. This information may help you make smarter investment decisions.
About EIGRQ
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development of therapies for hepatitis delta virus (HDV) and other serious diseases. Its HDV platform includes lonafarnib, an oral farnesylation inhibitor that targets a critical host process involved in viral replication. Its clinical product candidates include Lonafarnib (LNF) for HDV, Peginterferon Lambda (lambda) for HDV, Combination Therapy for HDV, and Peginterferon Lambda (lambda) for COVID-19. LNF is an orally bioavailable, farnesylation inhibitor that has completed a Phase 3 clinical trial for HDV infection. LNF has demonstrated dose-dependent activity in reducing HDV viral load both as a monotherapy and in combination with ritonavir (RTV) and/or PEG IFN-alfa-2a. Lambda is a type III, well-tolerated interferon (IFN), that stimulates immune responses that are critical for the development of host protection during viral infections.